Status:
UNKNOWN
Prevalence of Primary Aldosteronism in Atrial Fibrillation
Lead Sponsor:
Aristotle University Of Thessaloniki
Conditions:
Atrial Fibrillation
Primary Aldosteronism
Eligibility:
All Genders
18-100 years
Brief Summary
This is an observational prospective cross-sectional study, investigating the prevalence of primary aldosteronism in patients with atrial fibrillation.
Eligibility Criteria
Inclusion
- Established diagnosis of atrial fibrillation with a standard surface ECG tracing of at least 30 seconds (either paroxysmal or persistent or permanent).
Exclusion
- Diagnosis of primary aldosteronism
- Diagnosis of heart failure, treated with mineralocorticoid receptor antagonists
- Inability to be subjected to any confirmatory tests for primary aldosteronism
- Acute vascular event (acute coronary syndrome, stroke, acute peripheral vascular event) within last 6 months
- Renal replacement therapy
- Incompetence of unwillingness to provide written informed consent
Key Trial Info
Start Date :
September 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05973604
Start Date
September 1 2021
End Date
September 1 2024
Last Update
August 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ippokratio General Hospital
Thessaloniki, Greece, 54642